224 related articles for article (PubMed ID: 12813467)
21. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M
Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688
[TBL] [Abstract][Full Text] [Related]
22. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway.
Pervin S; Singh R; Hernandez E; Wu G; Chaudhuri G
Cancer Res; 2007 Jan; 67(1):289-99. PubMed ID: 17210710
[TBL] [Abstract][Full Text] [Related]
23. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
Dowling RJ; Zakikhani M; Fantus IG; Pollak M; Sonenberg N
Cancer Res; 2007 Nov; 67(22):10804-12. PubMed ID: 18006825
[TBL] [Abstract][Full Text] [Related]
24. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
Vanderweele DJ; Rudin CM
Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
[TBL] [Abstract][Full Text] [Related]
25. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
Tirado OM; Mateo-Lozano S; Notario V
Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
[TBL] [Abstract][Full Text] [Related]
27. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.
Troussard AA; McDonald PC; Wederell ED; Mawji NM; Filipenko NR; Gelmon KA; Kucab JE; Dunn SE; Emerman JT; Bally MB; Dedhar S
Cancer Res; 2006 Jan; 66(1):393-403. PubMed ID: 16397254
[TBL] [Abstract][Full Text] [Related]
28. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang S; Houghton PJ
Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
[TBL] [Abstract][Full Text] [Related]
30. Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling.
Joseph T; Bryant A; Frankel P; Wooden R; Kerkhoff E; Rapp UR; Foster DA
Oncogene; 2002 May; 21(22):3651-8. PubMed ID: 12032867
[TBL] [Abstract][Full Text] [Related]
31. 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer.
Baan B; Dihal AA; Hoff E; Bos CL; Voorneveld PW; Koelink PJ; Wildenberg ME; Muncan V; Heijmans J; Verspaget HW; Richel DJ; Hardwick JC; Hommes DW; Peppelenbosch MP; van den Brink GR
Gut; 2012 Dec; 61(12):1708-15. PubMed ID: 22187071
[TBL] [Abstract][Full Text] [Related]
32. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.
Rodrik V; Zheng Y; Harrow F; Chen Y; Foster DA
Mol Cell Biol; 2005 Sep; 25(17):7917-25. PubMed ID: 16107734
[TBL] [Abstract][Full Text] [Related]
33. Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR.
Lehman N; Ledford B; Di Fulvio M; Frondorf K; McPhail LC; Gomez-Cambronero J
FASEB J; 2007 Apr; 21(4):1075-87. PubMed ID: 17242159
[TBL] [Abstract][Full Text] [Related]
34. The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle.
Hornberger TA; Chu WK; Mak YW; Hsiung JW; Huang SA; Chien S
Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4741-6. PubMed ID: 16537399
[TBL] [Abstract][Full Text] [Related]
35. Studies on the mechanism of resistance to rapamycin in human cancer cells.
Hosoi H; Dilling MB; Liu LN; Danks MK; Shikata T; Sekulic A; Abraham RT; Lawrence JC; Houghton PJ
Mol Pharmacol; 1998 Nov; 54(5):815-24. PubMed ID: 9804616
[TBL] [Abstract][Full Text] [Related]
36. Targeting aspartate aminotransferase in breast cancer.
Thornburg JM; Nelson KK; Clem BF; Lane AN; Arumugam S; Simmons A; Eaton JW; Telang S; Chesney J
Breast Cancer Res; 2008; 10(5):R84. PubMed ID: 18922152
[TBL] [Abstract][Full Text] [Related]
37. HPV-16 E7 expression up-regulates phospholipase D activity and promotes rapamycin resistance in a pRB-dependent manner.
Rabachini T; Boccardo E; Andrade R; Perez KR; Nonogaki S; Cuccovia IM; Villa LL
BMC Cancer; 2018 Apr; 18(1):485. PubMed ID: 29703186
[TBL] [Abstract][Full Text] [Related]
38. Suppression of TGF-beta signaling by phospholipase D.
Gadir N; Lee E; Garcia A; Toschi A; Foster DA
Cell Cycle; 2007 Nov; 6(22):2840-5. PubMed ID: 18032924
[TBL] [Abstract][Full Text] [Related]
39. Investigation of Novel Regulation of N-myristoyltransferase by Mammalian Target of Rapamycin in Breast Cancer Cells.
Jacquier M; Kuriakose S; Bhardwaj A; Zhang Y; Shrivastav A; Portet S; Varma Shrivastav S
Sci Rep; 2018 Aug; 8(1):12969. PubMed ID: 30154572
[TBL] [Abstract][Full Text] [Related]
40. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
Herman JF; Mangala LS; Mehta K
Oncogene; 2006 May; 25(21):3049-58. PubMed ID: 16449978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
